Join to view full profile
13400 E Shea BlvdScottsdale, AZ 85259
Phone+1 480-301-8000
Fax+1 517-975-9511
Dr. Zakharia is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
McLaren Health Care/Greater Lansing/MSUFellowship, Hematology and Medical Oncology, 2011 - 2014- Rochester Regional Health/Unity Internal MedicineResidency, Internal Medicine, 2008 - 2011
Damascus University Faculty of MedicineClass of 2005
Certifications & Licensure
AZ State Medical License 2024 - 2027
IA State Medical License 2014 - 2025
GA State Medical License 2013 - 2015
MI State Medical License 2011 - 2015
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
- CMS Meaningful Use Stage 1 Certification Outgoing Public Health Reporting from EpicCare Functionality, Epic Systems Corporation, 2017
Clinical Trials
- SLM + Axitinib for Clear Cell RCC
- Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) Start of enrollment: 2019 Mar 20
- Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma Start of enrollment: 2019 Aug 27
Publications & Presentations
PubMed
- Body mass index at diagnosis, postdiagnosis change, and role of metabolic comorbidities in relation to survival in nonmetastatic renal cell carcinoma patients.Monica Sarker, Zhengyi Deng, Eric C Kauffman, Li Tang, Marilyn L Kwan
Cancer. 2026-11-01 - Advances in the management of renal cell carcinoma.Akeem R Lewis, Timothy D Lyon, Sounak Gupta, Yousef Zakharia, Bradley C Leibovich
BMJ. 2026-10-26 - Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial c...Yousef Zakharia, Bernard Doger de Spéville, Rafael Morales-Barrera, Irene Moreno, Deepak Kilari
Journal for Immunotherapy of Cancer. 2026-09-21
Journal Articles
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaPraful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology
- Inhibiting IDO Pathways to Treat Cancer: Lessons from the ECHO-301 Trial and BeyondYousef Zakharia, MD, Seminars in Immunopathology
Authored Content
- A Preview of 'Going Beyond RECIST: Radiomics in Kidney Cancer'October 2024
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Press Mentions
Ultimovacs : Q3 2022 Report and PresentationNovember 14th, 2022- Ultimovacs ASCO Phase I Data Shows 60% ORR in Advanced Melanoma with UV1/pembrolizumab, Supporting Broad Phase II Combination ProgramJune 4th, 2021
- ACE2 Pathway Stimulation Enhances VEGF Inhibition in ccRCC, May Help Overcome VEGF ResistanceFebruary 18th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: